Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MTX · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | - |
| B | ACTIVE_COMPARATOR | - |
| C | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| adalimumab | DRUG | 40 mg every other week following an 80 mg dose |
| MTX | DRUG | MTX 7.5 to 25 mg once weekly |
| placebo adalimumab, placebo MTX | DRUG | placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX) |
Inclusion Criteria: * Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history who has had a diagnosis of psoriasis for at least 12 months and stable moderate to severe chronic plaque psoriasis * Subject is a candidate for systemic therapy or pho...
MTX is a small molecule being studied for the treatment of moderate to severe chronic plaque psoriasis. It is being evaluated in a Phase 3 clinical trial as an active comparator against adalimumab and placebo. The drug is intended for use in adult patients with this dermatological condition.
MTX is a small molecule therapeutic. Its specific molecular target is not disclosed in the available clinical trial information. The drug is being investigated for its efficacy and safety in treating moderate to severe chronic plaque psoriasis, a condition characterized by scaly skin patches.
MTX is being developed by Abbott Laboratories, a company traded on the stock exchange under the ticker symbol ABT. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with moderate to severe chronic plaque psoriasis.
MTX is in Phase 3 clinical development. It has completed one Phase 3 trial with a total enrollment of 271 participants. The trial was a randomized, double-blind, placebo-controlled study conducted in the United States. MTX is still investigational and has not been approved by regulatory authorities.
MTX has been studied in one completed Phase 3 clinical trial with the identifier NCT00235820. The trial, titled 'Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis,' enrolled 271 participants in the United States. The study was randomized, double-blind, and placebo-controlled.
MTX is commonly used as an abbreviation for methotrexate, a medication used in the treatment of psoriasis and other conditions. In the context of the clinical trial NCT00235820, MTX refers to methotrexate, which was compared against adalimumab and placebo in patients with moderate to severe chronic plaque psoriasis.